FDA must prove fraud in Vioxx suits

Share this article:
Dealing a severe blow to more than a 1,000 Texas product liability cases involving Merck’s Cox-2 selective inhibitor Vioxx, a Texas federal judge ruled in April that a 2003 state law allowing tort claims to proceed if a drug company withheld from FDA material risk information is pre-empted because only the agency itself, not a Texas jury, can conclude that fraud had been committed.

Relying on a 2001 landmark medical device pre-emption ruling by the US Supreme Court (Buckman vs. Plaintiffs Legal Committee), Judge Randy Wilson said it is the FDA’s “exclusive responsibility” to police fraud. He noted that other courts have also concluded that to invoke “fraud-on-the-FDA” exceptions found in many state product liability laws, the agency must first determine that it had been defrauded.

Wilson also emphasized the Supreme Court’s concern that if state tort claims were permitted, “manufacturers might ‘deluge’ the FDA with information it neither needed nor wanted in order to defend state tort claims. This could potentially impede the regulatory process.”

Most of the consolidated Vioxx product liability cases in Texas contain an allegation that Merck failed to provide adequate warnings on Vioxx-related risks, the judge noted.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...